title: Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization.
abstract: OBJECTIVE
  To evaluate the short-term visual and anatomical outcomes and safety of intravitreal bevacizumab in subfoveal idiopathic choroidal neovascularization.
  
  
  METHODS
  Thirty-two eyes of 32 patients with idiopathic choroidal neovascularization received intravitreal bevacizumab (1.25 mg/0.05 mL) in this prospective, noncomparative, interventional case series. Injection was repeated if optical coherence tomography showed intraretinal edema, subretinal fluid, and/or pigment epithelial detachment at a 4-week interval. Ophthalmic evaluations included best-corrected visual acuity, optical coherence tomography, and fundus fluorescein angiography. Patients were followed up for at least 12 weeks.
  
  
  RESULTS
  The mean follow-up period was 4.2 months. At 12 weeks, the mean best-corrected visual acuity improved from 20/133 (median, 20/200) to 20/50 (median, 20/40) (P < .001). The mean central macular thickness was reduced from 314.37 microm to 236.84 microm (P < .001). At the final visit, 19 eyes (59%) had an improvement of best-corrected visual acuity of 3 or more lines, 11 eyes (34%) remained stable, and 2 eyes (6%) lost 3 or more lines. No significant ocular or systemic adverse effects were observed.
  
  
  CONCLUSIONS
  Short-term results suggest that intravitreal bevacizumab is safe and well tolerated in idiopathic choroidal neovascularization. Many patients showed marked improvement in visual acuity and a decrease in central macular thickness. Further evaluation with longer follow-up is needed to confirm long-term efficacy and safety.
authors.affiliation: Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India.
authors.forename: Subrata
authors.initials: S
authors.lastname: Mandal
authors.forename: Satpal
authors.initials: S
authors.lastname: Garg
authors.forename: Pradeep
authors.initials: P
authors.lastname: Venkatesh
authors.forename: Charu
authors.initials: C
authors.lastname: Mithal
authors.forename: Rajpal
authors.initials: R
authors.lastname: Vohra
authors.forename: Abhas
authors.initials: A
authors.lastname: Mehrotra
mesh_terms: D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005584:Fovea Centralis; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D019233:Retreatment; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000009:adverse effects / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab